Portfolio Managers Andy Acker and Agustin Mohedas explain why shares of companies delivering next-generation therapies for inflammation and immunology (I&I) disorders could have plenty of room to run.
Though healthcare may have flown under the market’s radar this year, the sector’s attractive valuations and new growth opportunities are not to be overlooked, say Janus Henderson's Portfolio Managers Andy Acker and Dan Lyons.
Fred Holt and Lina Ghayor join
More than four decades in industry
Janus Henderson Credit Risk Monitor Q1
Top year for systematic trend funds
Central bank raises rates to 1.75%